<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-167482</identifier>
<setSpec>1131-3587</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The management of patients with con coronary arterial disease (peripheral arterial disease or cerebrovascular disease). Going beyond symptoms</dc:title>
<dc:description xml:lang="en">Atherosclerosis is a widespread disease process that affects a range of different vascular territories and which gives rise to the clinical manifestations of ischemic heart disease, peripheral arterial disease and cerebrovascular disease. Although the details differ slightly, these conditions all share the same risk factors and pathogenesis. Consequently, their prevention and treatment are based on the control of these common risk factor and involve the use of antiplatelet agents, angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists, and statins combined with other measures particular to each condition. This article reviews the beneficial effects of these therapies and discusses indications for revascularization, whether through surgery or percutaneous angioplasty with stents, in cerebrovascular disease and peripheral arterial disease of the lower extremities (AU)</dc:description>
<dc:creator>Castillo, Juan C</dc:creator>
<dc:creator>Suárez de Lezo, José</dc:creator>
<dc:creator>Cejudo, Laura</dc:creator>
<dc:creator>Anguita, Manuel</dc:creator>
<dc:creator>Villanueva, Elena</dc:creator>
<dc:creator>Aguilera, José</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La aterosclerosis es un proceso difuso que afecta a diversas localizaciones vasculares y da lugar a las manifestaciones clínicas de la cardiopatía isquémica, la arteriopatía periférica y la enfermedad cerebrovascular. Aunque con pequeños matices, los factores de riesgo y la etiopatogenia son comunes a todas ellas, por lo que su tratamiento y su prevención se basan en el control de los factores de riesgo y en el uso de antiagregantes, IECA o ARA-II y estatinas, junto con otras medidas específicas de cada enfermedad. Se revisan los efectos beneficiosos de estos tratamientos, así como las indicaciones de revascularización, bien mediante cirugía, bien mediante angioplastia percutánea con stents, en la enfermedad cerebrovascular y la enfermedad arterial de las extremidades inferiores (AU)</dc:description>
<dc:source>Rev. esp. cardiol. Supl. (Ed. impresa);9(supl.D): 49d-55d, 2009. tab</dc:source>
<dc:identifier>ibc-167482</dc:identifier>
<dc:title xml:lang="es">Manejo terapéutico del paciente con arteriopatía no coronaria (enfermedad arterial periférica y/o enfermedad cerebrovascular): más allá de los síntomas</dc:title>
<dc:subject>^d53218^s22045</dc:subject>
<dc:subject>^d2586^s22012</dc:subject>
<dc:subject>^d2600^s22012</dc:subject>
<dc:subject>^d2586</dc:subject>
<dc:subject>^d53992^s22067</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d2359^s22012</dc:subject>
<dc:subject>^d2359^s22067</dc:subject>
<dc:subject>^d22965^s22000</dc:subject>
<dc:subject>^d53992^s22016</dc:subject>
<dc:subject>^d34247^s22054</dc:subject>
<dc:subject>^d3963^s22074</dc:subject>
<dc:subject>^d34247^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>200900</dc:date>
</metadata>
</record>
</ibecs-document>
